Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (161-170 of 596) with videos related to

Pageof 60
Sort By:
Phytotherapy Research : PTR|January 31, 2003
Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig modelJamie C Laurenz, Chad C Collier, Joseph O Kuti
Journal of Clinical Microbiology|July 26, 2019
Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone ConcentrationsIris H Chen, David P Nicolau, Joseph L Kuti
Journal of Critical Care|March 25, 2008
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysisEffie L Kuti, Aarti A Patel, Craig I Coleman
Surgical Infections|January 26, 2006
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA ProgramChristine T Ong, Joseph L Kuti, David P Nicolau, et al.
Connecticut Medicine|February 17, 2006
Polymyxins: older antibiotics for a new threatSu Young Lee, Joseph L Kuti, David P Nicolau
Surgical Infections|April 18, 2007
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profilingKathryn J Eagye, Joseph L Kuti, David P Nicolau
Diagnostic Microbiology and Infectious Disease|March 14, 2007
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentC Andrew DeRyke, Joseph L Kuti, David P Nicolau
Current Medical Research and Opinion|October 7, 2020
Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and bothChi Nguyen, Rakesh Luthra, Effie Kuti, et al.
Current Opinion in Infectious Diseases|October 3, 2020
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organismsAbigail K Kois, David P Nicolau, Joseph L Kuti
Antimicrobial Agents and Chemotherapy|November 3, 2020
Imipenem/Cilastatin/Relebactam Alone and in Combination against <i>Pseudomonas aeruginosa</i> in the <i>In Vitro</i> Pharmacodynamic ModelIris H Chen, David P Nicolau, Joseph L Kuti
Pageof 60

Showing results (161-170 of 596) with videos related to

Sort By:
Pageof 60
Phytotherapy Research : PTR|January 31, 2003
Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig modelJamie C Laurenz, Chad C Collier, Joseph O Kuti
Journal of Clinical Microbiology|July 26, 2019
Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone ConcentrationsIris H Chen, David P Nicolau, Joseph L Kuti
Journal of Critical Care|March 25, 2008
Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysisEffie L Kuti, Aarti A Patel, Craig I Coleman
Surgical Infections|January 26, 2006
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA ProgramChristine T Ong, Joseph L Kuti, David P Nicolau, et al.
Connecticut Medicine|February 17, 2006
Polymyxins: older antibiotics for a new threatSu Young Lee, Joseph L Kuti, David P Nicolau
Surgical Infections|April 18, 2007
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profilingKathryn J Eagye, Joseph L Kuti, David P Nicolau
Diagnostic Microbiology and Infectious Disease|March 14, 2007
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessmentC Andrew DeRyke, Joseph L Kuti, David P Nicolau
Current Medical Research and Opinion|October 7, 2020
Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and bothChi Nguyen, Rakesh Luthra, Effie Kuti, et al.
Current Opinion in Infectious Diseases|October 3, 2020
Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organismsAbigail K Kois, David P Nicolau, Joseph L Kuti
Antimicrobial Agents and Chemotherapy|November 3, 2020
Imipenem/Cilastatin/Relebactam Alone and in Combination against <i>Pseudomonas aeruginosa</i> in the <i>In Vitro</i> Pharmacodynamic ModelIris H Chen, David P Nicolau, Joseph L Kuti
Pageof 60